Drug intelligence / Profile preview

ADSCs-Exo + Sflt-1

Development stage
Preclinical
Modality
Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

ADSCs-Exo + Sflt-1 is an experimental, preclinical gene-loaded exosome biologic designed to treat rheumatoid arthritis-associated interstitial lung disease (RA-ILD). It consists of exosomes derived from adipose-derived stem cells (ADSCs) engineered to deliver the soluble vascular endothelial growth factor receptor 1 (Sflt-1) gene. Sflt-1 acts as a decoy receptor that binds to and antagonizes vascular endothelial growth factor (VEGF), thereby inhibiting VEGF-mediated angiogenesis and inflammation. In preclinical mouse models, this therapy has demonstrated the ability to alleviate both joint inflammation and pulmonary fibrosis/inflammation by reducing pro-inflammatory cytokines (IL-1β, IL-6, IL-17A) and pro-fibrotic factors (TGF-β, VCAM).

Other names
adipose-derived stem cell-derived exosomes packaging Sflt-1mesenchymal stem cell-derived exosomes packaging Sflt-1
02

Targets

VEGFB (Vascular endothelial growth factor B)PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on ADSCs-Exo + Sflt-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADSCs-Exo + Sflt-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call